

## Saraswati Education Society's

### YADAVRAO TASGAONKAR INSTITUTE OF PHARMACY



( Recognized by PCI, Approved by DTE-PH-3232, Affiliated to University of Mumbai)

SES/YTIP/lett./2019-03

20 March 2019

To Principal Oriental College of Pharmacy

Sanpada, Navi Mumbai

Sub.: No-Objection Certificate for pursuing PhD at OCP

Dear Mam,

We have no objection if Ms. Puja Gulabrao Vyawhare an employee of our organization/institute, is admitted to the Ph.D. Programme in the Department of pharmaceutics at Oriental College of Pharmacy Sanpada, Navi Mumbai, It is certified that she has completed 8 year(s) of service in our organization/institute as a regular employee. We shall give her leave of absence at our organization to attend classes of course work of Ph.D. programme.

PRINCIPAL
PRINCI

Signature & Seal of ried of the organization/ Institute



Dr. (Mrs.) Sudha Rathod Principal Oriental College of Pharmacy Plot No. 3, 4 & 5, Sector-2, Sanpada, Navi Mumbal



## https://africanjournalofbiomedicalresearch.com/index.php/AJBR

Afr. J. Biomed. Res. Vol. 27(4S) (November 2024); 787 -806 Research Article

# Systematic physicochemical characterization of potent anticancer drug paclitaxel loaded solid lipid nanoparticles with herbal adjuvants

Prof. Puja Vyawhare<sup>1\*</sup>, Prof. Dr. Sudha Rathod<sup>2</sup> Prof. Dr. Rupali Tasgaonkar<sup>3</sup>, Prof. Anjali Rai<sup>5</sup> Prof. Dr. Babita More<sup>6</sup>

<sup>1</sup>Assistant Professor, Yadavrao Tasgaonkar Institute of Pharmacy, Karjat, Mail id: vyawharepooja@gmail.com\*

<sup>2</sup>Principal, OES Oriental College of Pharmacy, Navi Mumbai, mail id:<u>sudharathod@gmail.com</u>
<sup>3</sup>Principal, Yadavrao Tasgaonkar Institute of Pharmacy, Karjat, Mail id:

\*Asst Professor, Shri D D Vispute College of Pharmacy & Research Center, NewPanvel,mail id:

<sup>5</sup>Assistant Professor, OES Oriental College of Pharmacy, Navi Mumbai, mail id:<u>anjali.rai@ocp.edu.in</u>

<sup>6</sup>Associate Professor, Yadavrao Tasgaonkar Institute of Pharmacy, Karjat, Mail id:

<u>babita.more@tasgaonkartech.com</u>

### ABSTRACT:

The purpose of the study was to develop and analyze a solid lipid nanoparticle (SLN)-based Paclitaxel drug delivery system. The SLN's lipid & surfactant components were oleic acid & soy lecithin (Tween 80). Numerous batches of paclitaxel-containing solid lipid nanoparticles were produced using size-reduction methods, solvent emulsification by ultrasonication, and different drug and lipid doses. Excipients were employed in tests where the formulation characteristics wereimproved by varying the ratios of medicines, lipids, and surfactants. The created formulationsunderwent assessments in the areas of drug content, in-vitro drug release, particle size analysis, scanning electron microscopy, Fourier transforminfrared studies, differential scanning calorimetry, and stability. Additionally, it was discovered that the improved formulation performed well with each of the formulation's constituents as demonstrated by FTIR and DSC data. The solid lipid nanoparticles that were created have a size of 200.01 nm. After three months at 5±3 °C and 25±2 °C/60±5% RH, the improved formulation showed no significant modifications in appearance, drug content (%), drug entrapment efficiency (%), or in vitro drug release (%).

KEYWORDS: Drug Delivery, Paclitaxel, Solid Lipid Nanoparticles, Anticancer Medication, and Particle Size

\*Author for correspondence: Email: vyawharepooja@gmail.com

Received: 01November 2024 Accepted: 13 November 2024

DOI: https://doi.org/10.53555/AJBR.v27i4S.3690

© 2024 The Author(s).

This article has been published under the terms of Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. This article has been published in the African Journal of Biomedical Research.

NAVI MUMBAI 400 706

Dr. (Mrs.) Sudha Rathod

787

Afr. J. Biomed. Res. Vol. 27, No.4s (November) 2024 | College of Prof. Ruig Vyawhare et al

White Powder 88.6
0.6.1
86.1
97.8
286
-3.2

Table 13.: Stability Studies for the Optimized Batch (Batch 5)

#### 9. CONCLUSION:

According to a review of the literature, Paclitaxel-loaded solid lipid nanoparticles were prepared using Soy Lecithin and Oleic Acid as lipids and Papain as a herbal extract using an array of drug:lipid proportions via Solvent Emulsification, and the prepared nanoemulsion was lyophilized using Freeze Drying. Batch 5's drug:lipid ratio of 0.6 g Paclitaxel (drug), 1.2 g Soy Lecithin (lipid), and 0.6 g Oleic Acid (lipid) produced satisfactory results and was found to be more reproducible with the highest drug content (%), drug entrappientefficiency (%), and in vitro drug release (%), so it was considered the optimal formulation. Paclitaxel and Papain were shown to be pure by FTIR and DSC analysis. Pre-formulation experiments revealed that Paclitaxel and Papain have the highest solubility in methanol. The optimized formulation was also determined to be compatible with all of the formulation's constituents, as demonstrated by FTIR and DSC data. The size of the intended solid lipid nanoparticles was 300.01 nm. The optimized formulation (Batch 5) remained stable for 3 months at  $5\pm3$  ° C and  $25\pm2$  ° C/60 ± 5% RH. There was no significant change in appearance, drug entrapment efficiency (%), drug content (%), or invitro drug release (%).

### 10. REFERENCE:

- 1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nano-Enabled Medical Applications. 2020Nov23:61-91.
- 2. Suri SS, Fenniri H, Singh B. Nanotechnology-based drug delivery systems. Journal of occupational medicineand toxicology. 2007 Dec;2(1):1-6.
- 3. Cho K, Wang XU, Nie S, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clinical cancer research. 2008 Mar 1;14(5):1310-6.
- 4. Wilczewska AZ, Niemirowicz K, Markiewicz KH, Car H. Nanoparticles as drug delivery systems. Pharmacological reports. 2012 Sep 1;64(5):1020-37.
- 5. Bhatia S. Nanoparticles types, classification, characterization, fabricationmethods and drug delivery applications.InNatural polymer delivery systems 2016 (pp. 33-93). Springer, Cham.
- 6. Hasan S. A review on nanoparticles: their synthesis and types. Res. J. Recent Sci. 2015;2277:2502.
- 7. Buabeid MA, Arafa ES, Murtaza G. Emerging prospects for nanoparticle- enabled cancer immunotherapy. Journal of Immunology Research. 2020 Jan 3;2020.
- 8. Lingayat VJ, Zarekar NS, Shendge RS. Sand Jibit G

- review.Nanoscience nanoparticles: Nanotechnology Research. 2017 Apr;4(2):67-72.
- 9. Awasthi R, Roseblade A, Hansbro PM, Rathbone MJ, Dua K, Bebawy M. Nanoparticles in cancer treatment: opportunities and obstacles. Current drug targets. 2018 Oct1;19(14):1696-709.
- 10. Ekambaram P, Sathali Aa, Priyanka K. Solid Lipid Nanoparticles: A Review
- 11. Priyadarshini K, Keerthi AU. Paclitaxel in cancer treatment: a brief overview. Med Chem. 2012 Nov;2(7):139-41.
- 12. Jones TM. Preformulation Studies.
- Savjani JK. 13. Savjani KT, Gajjar AK, and significance and Drug.Solubility: International enhancementTechniques: ScholarlyResearch Notices 2012;2012.
- 14. Gannimitta, Arvind; Srinivas, Prathima.& A, Sobhita. Pedireddi, Venkateshwar; (2019). Preparation, Physical Characterization, And Pharmacokinetic Study Of Docetaxel Nanocrystals. Asian Journal Of Pharmaceutical And Clinical Research.238-244.10.22159/Ajpcr 2019.V12i6.32856.
- 15. da Rocha MC, da Silva PB, Radicchi MA, Andrade BY, de Oliveira JV, Venus T, Merker C, Estrela-Lopis I, Longo JP, Báo SN. Docetaxel-loaded solid lipid nanoparticles prevent tumor growth andlung metastasis of 4T1 murine mammary carcinoma cells. Journal of nanobiotechnology. 2020 Dec;18(1):1-20.
- 16. Devi TR, Gayathri S. FTIR and FT- Raman spectral analysis of Paclitaxeldrugs. Int JPharm Sci Rev Res. 2010;2(2):106-10.
- 17. Pooja D, Tunki L, Kulhari H, Reddy BB, Sistla R. Optimization of solid lipid nanoparticlesprepared by a single emulsification-solvent evaporation method. Data in brief.2016 Mar 1;6:15-9.
- 18. Mukherjee S, Ray S, Thakur RS. Solid lipid nanoparticles: a modern formulation approach in delivery system. Indian journal pharmaceutical sciences. 2009 Jul;71(4):349.
- 19. Yang T, Cui FD, Choi MK, Lin H, Chung SJ, Shim CK, Kim DD. Liposome formulation of Paclitaxel with enhancedsolubility and stability. Drug delivery. 2007 Jan 1;14(5):301-8.
- 20. Nandini PT, Doijad RC, Shivakumar HN, Dandagi PM. Formulation and evaluation of gemcitabineloaded solid lipidnanoparticles. Drug delivery. 2015 Jul 4;22(5):647-51.
- 21. Zhang JQ, Liu J, Li XL, Jasti BR. Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug delivery. 2007 Jan 1;14(6):381-7.

Afr. J. Biomed. Res. 76

27 No.45 (November) 2014. (Mrs.) Sucha Prof. Puja Vyawhare et al

Systematic physicochemical characterization of potent anticancer drug paclitaxel loaded solid lipid nanoparticles with herbal adjuvants

- 22. Agubata CO, Chime SA, Kenechukwu FC, Nzekwe IT, Onunkwo GC. Formulation and characterisation of hydrochlorothiazide solid lipid microparticles using lipid matrices: Irvingia fat; International Journal of Pharmaceutical Investigation, 2014. Oct;4(4):189.
- 23. [23]. Venishetty V.K., Parikh N., Sistla R. Ahmed FJ and Diwan PV. Application of ValidatedRP-HPLC Method for The simultaneous determination of docetaxel and ketoconazole in solid lipid nanoparticles. Journal of chromatographic science. 2011 Feb 1;49(2):136-41.
- 24. Sharma M, Kohli S, Dinda A. In-vitro and in-vivo evaluation of repaglinide loaded floating microspheres prepared from different viscosity grades of HPMC polymer. Saudi pharmaceutical journal. 2015 Nov 1;23(6):675-82.
- 25. Devi TR, Gayathri S. FTIR and FT- Raman spectral analysis of Paclitaxel drugs. Int J Pharm Sci Rev Res. 2010;2(2):106-10.
- 26. Raza K., Singh B, Singal P, Wadhwa S, Katare OP. Systematically optimized biocompatible isotretinoin-loaded solid lipid nanoparticles (SLNs) for topicaltreatment of acne. Colloids and Surfaces B: Biointerfaces. 2013 May 1;105:67-74.



Alathora -

Dr. (Mrs.) Sudha Rathod Principal Oriental College of Pharmacy Plot No. 3, 4 & 5, Sector-2, Sanpada, Navi Mumbal.